Lantern Pharma

Lantern Pharma is at the forefront of transforming oncology drug discovery and development through the power of AI, machine learning, and genomics. The company's approach addresses the significant challenges in oncology drug development, including high costs, lengthy timelines, and low success rates. Lantern Pharma's core technology, the RADR® (Response Algorithm for Drug Positioning & Rescue) AI platform, is designed to accurately stratify patient populations into responders and non-responders for various oncology therapies. This approach aims to de-risk clinical trials, develop companion diagnostics, and increase the potential for successful FDA approval while reducing costs. The company focuses on precision oncology, rescuing and repositioning abandoned cancer drugs, and developing a portfolio of drug candidates targeting various types of cancer. Lantern Pharma's innovative approach is particularly relevant given that biomarker-based trials are 12 times more likely to succeed in the oncology field. By leveraging AI and data-driven methodologies, Lantern Pharma is working to accelerate the pace of drug development and improve outcomes for cancer patients.